Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA M1043V |
Therapy | Alpelisib |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA M1043V | head and neck squamous cell carcinoma | predicted - sensitive | Alpelisib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, treatment with Piqray (alpelisib) resulted in inhibition of proliferation and increased apoptosis in a head and neck squamous cell carcinoma (HNSCC) cell line expressing PIK3CA M1043V in culture and led to inhibition of tumor growth and decreased phosphorylated Akt levels in a patient-derived xenograft (PDX) model of HNSCC with PIK3CA M1043V (PMID: 34779417). | 34779417 |
PubMed Id | Reference Title | Details |
---|---|---|
(34779417) | Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. | Full reference... |